BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38550598)

  • 21. Efficacy and cost-effectiveness analysis of pretreatment percutaneous endoscopic gastrostomy in unresectable locally advanced esophageal cancer patients treated with concurrent chemoradiotherapy (GASTO 1059).
    Ai X; Zhang P; Xie X; Qiu B; Zhu Y; Zhao L; Xi M; Wu Y; Guo S; Guo J; Liu F; Wang D; Chen N; He Q; Hu Y; Liu M; Ding Z; Liu H
    Cancer Med; 2023 Jul; 12(14):15000-15010. PubMed ID: 37326436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Frailty on Treatment Outcome in Patients With Locally Advanced Esophageal Cancer Undergoing Concurrent Chemoradiotherapy.
    Huang YH; Hung YS; Lai CC; Ho MM; Yeh KY; Yang C; Lu CH; Tseng CK; Tsang NM; Hung CY; Hsueh SW; Chang PH; Ho YW; Lin YC; Chou WC
    Anticancer Res; 2021 Oct; 41(10):5213-5222. PubMed ID: 34593474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival comparision of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma.
    Tan L; Xiao Z; Zhang H; Chen D; Feng Q; Zhou Z; Lv J; Liang J; Yin W
    Cancer Radiother; 2020 Feb; 24(1):21-27. PubMed ID: 32001131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.
    Liu A; Wang Y; Wang X; Zhu L; Nie Y; Li M
    Radiat Oncol; 2021 Oct; 16(1):195. PubMed ID: 34600574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.
    Lyu J; Li T; Wang Q; Li F; Diao P; Liu L; Li C; Lang J
    Radiat Oncol; 2018 Nov; 13(1):233. PubMed ID: 30477531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
    Yao B; Tan B; Wang C; Song Q; Wang J; Guan S; Jia Y; Ma Y; Huang X; Sun Y; Cheng Y
    Ann Surg Oncol; 2016 Jul; 23(7):2367-72. PubMed ID: 26932711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Esophageal Metal Stents with Concurrent Chemoradiation Therapy for Locally Advanced Esophageal Cancer: Safe or Not?
    Lu YF; Chung CS; Liu CY; Shueng PW; Wu LJ; Hsu CX; Kuo DY; Hou PY; Chou HL; Leong KI; How CH; Chou SF; Wang LY; Hsieh CH
    Oncologist; 2018 Dec; 23(12):1426-1435. PubMed ID: 29728468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
    Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Huang CC; Shih LH; Chen SW; Li SH
    BMC Cancer; 2018 Aug; 18(1):837. PubMed ID: 30126380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma.
    Chen H; Zhou L; Yang Y; Yang L; Chen L
    Med Sci Monit; 2018 Jun; 24():4183-4191. PubMed ID: 29915168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
    Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
    J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
    Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
    Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Jing W; Yan W; Liu Y; Li J; Yu J; Zhu H
    Cancer Biol Ther; 2019; 20(8):1121-1126. PubMed ID: 30983494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
    Ren XJ; Wang L; Han C; Liu LL
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144
    [No Abstract]   [Full Text] [Related]  

  • 34. Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
    Chang CL; Tsai HC; Lin WC; Chang JH; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Radiother Oncol; 2017 Oct; 125(1):73-79. PubMed ID: 28923576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival Comparision of Three-dimensional Radiotherapy Alone vs. Chemoradiotherapy for Esophageal Squamous Cell Carcinoma.
    Zhang AD; Su XH; Shi GF; Han C; Wang L; Liu H; Zhang J; Zhang RH
    Arch Med Res; 2020 Jul; 51(5):419-428. PubMed ID: 32418649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
    Li J; Gong Y; Diao P; Huang Q; Wen Y; Lin B; Cai H; Tian H; He B; Ji L; Guo P; Miao J; Du X
    Radiat Oncol; 2018 Jan; 13(1):12. PubMed ID: 29357883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study.
    Yin Y; Zhou Z; Li Z; Shen M; Qin Y; Yang C; Wang R; Kang M
    Radiat Oncol; 2022 Jul; 17(1):135. PubMed ID: 35906636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis.
    Wang J; Xiao L; Wang S; Pang Q; Wang J
    Front Oncol; 2021; 11():665231. PubMed ID: 34589418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent chemoradiotherapy combined with enteral nutrition support: a radical treatment strategy for esophageal squamous cell carcinoma patients with malignant fistulae.
    Ma L; Luo GY; Ren YF; Qiu B; Yang H; Xie CX; Liu SR; Liu SL; Chen ZL; Li Q; Fu JH; Liu MZ; Hu YH; Ye WF; Liu H
    Chin J Cancer; 2017 Jan; 36(1):8. PubMed ID: 28077159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
    Chen WM; Yu YH; Chen M; Shia BC; Wu SY
    J Thorac Oncol; 2023 Aug; 18(8):1082-1093. PubMed ID: 37085031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.